Percutaneous Thermal Ablation in Lung Tumors

Lung cancer has a high incidence globally, with Egypt having it as the third most common and most lethal cancer, affecting 16.9% of males and 3.8% of females. While surgery is the preferred treatment for stage 1 non-small cell lung cancer due to positive outcomes, it carries significant risks due to patient comorbidities. Non-invasive treatments like radio frequency ablation (RFA) and microwave ablation (MWA) are alternatives for those unable to undergo surgery. These techniques use energy to destroy tumor tissue with minimal invasiveness and can be guided by computed tomography to ensure accu

Trial Details

NCT ID
NCT06891183
Phase
NA
Sponsor
Assiut University
Status
RECRUITING
Cancer Type
Small Cell (SCLC) Lung Cancer
Interventions
  • Percutaneous thermal ablation of lung tumors
Locations (sample)
  • Asyut, Egypt|27.18096,31.18368

Key Eligibility Criteria

  • lung cancer smaller than 5 cm
  • metastasis to the lung
  • patients with lung cancer and multiple comorbidities who are unfit for surgery

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Small Cell (SCLC) Lung Cancer Trials on Trialify →